SynapSeek fuses six clinical data streams into a single intelligence platform — delivering pre-symptomatic diagnosis, full care pathway tracking, and the longitudinal dataset that will define the next era of neurology.
Neurological conditions are the leading cause of disability on Earth — affecting 3 billion people globally and costing the world $2.8 trillion annually. Yet the average patient is diagnosed years after the disease has already caused irreversible damage.
The tools that clinicians rely on — MRI, cognitive assessments, single-biomarker blood tests — are powerful in isolation, but blind to the early signal. That signal exists. It is present in the combination of imaging, blood biomarkers, genetic data, and real-time wearable monitoring — years before a single structural change appears on a scan.
No platform has ever integrated all of them. Until now.
"The tragedy of neurological disease is not that it cannot be detected early. It is that the tools to do so have never existed in the same room."
SynapSeek identifies neurological disease signals 7 to 10 years before the first symptom appears — in the window when intervention is most effective and when no other tool is looking.
Our platform simultaneously processes MRI, PET scans, blood biomarkers, electronic health records, genomics, and wearable data — fused through a proprietary AI architecture that treats the patient as a system, not a collection of tests.
SynapSeek does not stop at diagnosis. The platform tracks treatment response, lifestyle changes, and disease trajectory against each patient's own baseline — closing the clinical loop from first signal to long-term outcome.
Patient data is accepted from existing clinical systems — PACS, EHR, lab systems, and wearables — with no new equipment and no workflow disruption. Available as a web portal for smaller clinics, or a direct API and PACS plugin for health systems.
SynapSeek's H-GNN (Heterogeneous Graph Neural Network) architecture maps biological relationships across all six data streams simultaneously — producing a unified picture that no single modality can provide.
Every output includes a 3D brain attention map, ranked biomarker driver list, and a confidence score — a full reasoning chain, not a black box. Designed to support the clinician's judgment, not replace it.
Stage classification, referral pathway, and — over time — longitudinal tracking of treatment response and disease progression against the patient's own baseline. The record that grows with every visit.
A 45-year-old presents with persistent headaches and wearable-flagged HRV decline. MRI is ordered. The radiologist reads it: structurally unremarkable. Blood panel results are individually inconclusive. The case closes. The disease continues.
The same patient. The same data. SynapSeek cross-references the imaging with elevated p-Tau 217, NfL markers, and the HRV pattern — detecting an early neurodegenerative signal in the combination that no single test showed. Neurologist referral recommended. Years of intervention window preserved.
The dataset that links pre-symptomatic signal to long-term care outcomes — in the same patient, over time — does not exist anywhere. We are building it.
Wearable HRV drift. Sleep pattern degradation. Subtle cognitive markers. SynapSeek is watching.
Blood biomarker elevation — p-Tau 217, NfL, GFAP. fMRI connectivity shifts. Still invisible to standard imaging.
Multimodal fusion delivers stage classification, confidence score, and referral pathway. Years earlier than the clinical standard.
Treatment initiation, lifestyle intervention, drug response — all tracked against the patient's own baseline. A clinical record no one else holds.
Disease trajectory modeling. Treatment efficacy signals. The foundation for personalised medicine and the dataset that changes what drug development looks like.
Stages 4 and 5 represent SynapSeek's longitudinal care tracking layer — a capability no competitor currently offers.
SynapSeek was validated on the Alzheimer's Disease Neuroimaging Initiative (ADNI) — the world's most credentialed neuro MRI and biomarker repository. Validation was performed on a held-out test set, meaning the model was evaluated on data it had never seen during training. The result is reproducible and peer-reviewable. This is not a demo. It is a clinical-grade performance benchmark.
Building SynapSeek since 2023 — two years before incorporation. 15+ years across global organisations including PwC. $500M+ in product revenues and $100M+ in cost savings across healthcare and technology.
Over a decade as a researcher in neuroimaging, brain-machine interfaces, and neurovascular modeling. Ph.D. in Neuroengineering from UIUC. Postdoctoral Researcher in Neurosurgery at Stanford. FDA-aligned clinical pathway experience.
Managing Director at Chaanakya Capital, a NeuroTech-focused venture fund. Active investor and board member across the neuro-tech ecosystem. Previously at Roblox and Walmart. Leads SynapSeek's corporate affairs and venture relationships.
BS and MS in Computer Science from Stanford, specializing in Visual Computing and AI. 5+ years in software engineering, 3+ years in AI/ML, and 3+ years of combined neuroscience study. Designed and built the H-GNN fusion architecture.
SynapSeek was incorporated in 2025, but the research and development behind the platform began in 2023. Dr. Vega Leonel has spent over a decade as a researcher in the clinical domain SynapSeek serves. This is not a team that found an opportunity. It is a team that built toward one.
One of the most cited neurosurgeons in the United States and former Chair of Neurosurgery at Duke. Award-winning researcher in neurological outcomes. His involvement provides SynapSeek with the highest tier of clinical neurosurgery credibility.
Ph.D. in Materials Engineering. Develops AI-driven imaging algorithms and biomaterial strategies for early-stage disease detection at Johns Hopkins. Her work on multi-modal biomarker identification is directly adjacent to SynapSeek's fusion architecture.
Ph.D. in Chemistry. Expert in neurological drug discovery and clinical translation, with multimillion-dollar research leadership across Johns Hopkins and St. Jude. Directly relevant to SynapSeek's pharma data licensing and drug simulation roadmap.
Three Johns Hopkins-connected advisors. A Duke neurosurgery department chair. Advisory relationships built on scientific respect — not advisory board decoration.
SynapSeek is building a small, selective cohort of founding data and pilot partners — academic medical centers, research universities, hospitals, and clinics who will co-create the world's first 6-modality longitudinal neuro dataset.
Founding partners receive joint publication rights, priority commercial deployment, preferential licensing terms, and proportional rights to the dataset as it appreciates in value.
We are not looking for the largest institutions. We are looking for the right ones.
SynapSeek is raising a $5M SAFE at a $25M valuation cap. This capital funds the clinical pilot program, multi-site validation study, and the regulatory pathway to FDA clearance.
A sovereign wealth fund has expressed Series A interest at nine figures. A global medtech and digital solutions innovator is engaged in deep partnership & integration discussions. A national health ministry is ready to deploy at scale.
The investors who move at seed capture the most asymmetric return.
